Company profile: Vivoryon Therapeutics
1.1 - Company Overview
Company description
- Provider of biopharmaceutical R&D and clinical development focused on small molecule medicines for Alzheimer’s disease and cancer, including varoglutamstat (QPCT inhibitor, Phase 2) and a portfolio of QPCT/L inhibitors, supported by a comprehensive clinical program. Holds a strategic licensing partnership with Simcere for varoglutamstat and a preclinical monoclonal N3pE‑antibody in Greater China.
Products and services
- Varoglutamstat: A Phase 2 clinical-stage, orally administered small‑molecule QPCT inhibitor engineered for Alzheimer’s disease, precisely targeting glutaminyl cyclase (QPCT) to inhibit enzyme activity
- Clinical Development Program: A comprehensive small‑molecule medicine program that architects research, preclinical and clinical trials across Alzheimer’s disease and cancer, advancing assets such as varoglutamstat
- QPCT/L Inhibitors: An in vivo–characterized portfolio of small‑molecule compounds for severe diseases, featuring over 49 inhibitors targeting QPCT/L enzymes for therapeutic advancement
Key contacts
🔒
🔒
Financial details
🔒
1.2 - Competitors and similar companies to Vivoryon Therapeutics
Trophos
HQ: France
Website
- Description: Provider of clinical-stage pharmaceutical R&D developing innovative therapeutics for under-served needs in neurology and cardiology, with a pipeline of original molecules targeting motoneuron diseases such as amyotrophic lateral sclerosis (ALS).
- Rationale: This competitor operates in a highly similar market segment with overlapping features.
- Company type: Private company
- Employees: ●●●●●
- Total funding raised: $●●●m
- Backers: ●●●●●●●●●●
- Acquisitions: ●●
View full Trophos company profile →
Zynex Medical
HQ: United States
Website
- Description: Provider of medical devices of its own design, engineered, manufactured, marketed, and sold by Zynex through three subsidiaries.
- Rationale: This competitor operates in a highly similar market segment with overlapping features.
- Company type: Private company
- Employees: ●●●●●
- Total funding raised: $●●●m
- Backers: ●●●●●●●●●●
- Acquisitions: ●●
View full Zynex Medical company profile →
Cypress Bioscience
HQ: United States
Website
- Description: Provider of therapeutics and personalized medicine services to facilitate individualized patient care, addressing needs such as isolated areas of pain, rheumatology, and physical medicine and rehabilitation.
- Rationale: This competitor operates in a highly similar market segment with overlapping features.
- Company type: Private company
- Employees: ●●●●●
- Total funding raised: $●●●m
- Backers: ●●●●●●●●●●
- Acquisitions: ●●
View full Cypress Bioscience company profile →
Burl Concepts
HQ: United States
Website
- Description: Provider of a portable, battery-powered ultrasound device for non-invasive, transcranial brain perfusion assessment and stroke diagnosis. The SONAS system uses microbubble contrast agents to detect cerebral blood perfusion differences.
- Rationale: This competitor operates in a highly similar market segment with overlapping features.
- Company type: Private company
- Employees: ●●●●●
- Total funding raised: $●●●m
- Backers: ●●●●●●●●●●
- Acquisitions: ●●
View full Burl Concepts company profile →
Liftware
HQ: United States
Website
- Description: Provider of electronic stabilizing and leveling utensil handles with interchangeable attachments (soup spoon, everyday spoon, fork, spork), designed to help people eat more easily by reducing utensil shaking for hand tremor and keeping utensils level for limited hand or arm mobility.
- Rationale: This competitor operates in a highly similar market segment with overlapping features.
- Company type: Private company
- Employees: ●●●●●
- Total funding raised: $●●●m
- Backers: ●●●●●●●●●●
- Acquisitions: ●●
View full Liftware company profile →
🔒
2.M&A buyers
2.1 Potential strategic acquirers in the sector
🔒
🔒
🔒
🔒
View all strategic buyers with complete profiles
Start Free Trial →
2.2 - Strategic buyer groups for Vivoryon Therapeutics
🔒
Buyer group 1: ████████ ████████
●● companies
Description: ████████ ████████ ████████ ████████ ████████ ████████ ████████ ████████ ████████ ████████
Key Products: ████████, ████████, ████████, ████████
🔒
View all companies in this group
Request Free Trial Now →
🔒
Buyer group 2: ████████ ████████
●● companies
Description: ████████ ████████ ████████ ████████ ████████ ████████ ████████ ████████ ████████ ████████
Key Products: ████████, ████████, ████████, ████████
🔒
View all companies in this group
Request Free Trial Now →
🔒
Buyer group 3: ████████ ████████
●● companies
Description: ████████ ████████ ████████ ████████ ████████ ████████ ████████ ████████ ████████ ████████
Key Products: ████████, ████████, ████████, ████████
🔒
View all companies in this group
Request Free Trial Now →
🔓 Unlock all detailed buyer group breakdowns with complete company profiles
Start Free Trial →
3. Investors and private equity firms
3.1 - Buyout funds investing in similar companies to Vivoryon Therapeutics
2.2 - Growth funds investing in similar companies to Vivoryon Therapeutics
🔒
View all growth equity funds with complete profiles
Start Free Trial →
4 - Top valuation comps for Vivoryon Therapeutics
4.2 - Public trading comparable groups for Vivoryon Therapeutics
🔓 Unlock all public trading comparable groups with complete valuation data
Start Free Trial →